National Cancer Institute study finds larger per-capita cancer increases in Generation X, particularly pancreatic cancer; biotech companies develop innovative treatments.
Study by National Cancer Institute reveals Generation X with larger per-capita cancer increases, particularly pancreatic cancer. Biotech companies like Oncolytics Biotech Inc., Verastem, Candel Therapeutics, FibroGen, and Regeneron Pharmaceuticals are developing innovative treatments for pancreatic cancer; Oncolytics presents two abstracts on novel immunotherapy pelareorep at ASCO Annual Meeting. Verastem shares positive initial interim safety and efficacy results in an ongoing trial.
June 12, 2024
3 Articles